Success Stories: NIW Approval Secured for Postdoctoral Research Fellow Advancing Early Diagnosis of Neurodegenerative Diseases
Client’s Testimonial:
“Based on my personal experience, the NAILG legal team showed exceptional efficiency, consistently available, timely in their responses, and always suggesting optimal solutions. They dedicated significant effort to my case and were confident in their work, even after receiving an RFE. They will always have a strategy to tackle every issue. I would wholeheartedly recommend their services to everyone.”
On August 27th, 2025, we received another EB-2 NIW (National Interest Waiver approval for a Postdoctoral Research Fellow in the field of Neuroscience (Approval Notice).
General Field: Neuroscience
Position at the Time of Case Filing: Postdoctoral Research Fellow
Country of Origin: Egypt
Country of Residence at the Time of Filing: Minnesota
Approval Notice Date: August 27th, 2025
Processing Time: 6 months and 14 days (Premium Processing Requested)
Case Summary:
We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to a postdoctoral research fellow from Egypt whose research is advancing early detection and treatment approaches for neurodegenerative diseases. At the time of filing, the client was engaged in research at a leading US medical center, focusing on integrating neuroimaging and neuropathology to improve the diagnosis of complex brain conditions. North America Immigration Law Group (NAILG) prepared and filed his petition with direct premium service, which was approved in 6 months and 14 days despite receiving an RFE.
Proposed Endeavor: Advancing Neuroimaging and Neuropathology for Early Diagnosis of Neurodegenerative Diseases
The client’s proposed endeavor focuses on developing integrated neuroimaging and neuropathology techniques for the premortem detection of TDP-43 proteinopathy, a hallmark of several neurodegenerative diseases such as ALS and dementia. His work provides innovative biomarkers that enable earlier diagnosis, more effective treatments, and improved outcomes for patients. These efforts directly address the urgent public health and economic challenges posed by rising rates of dementia and other age-related neurological conditions in the United States.
Notable Achievements Supporting the Petition
To demonstrate his eligibility for the NIW, NAILG emphasized the following accomplishments:
- Education and Training: Earned an M.B.B.Ch. and completed further advanced training in neurology and neuroscience, establishing a strong foundation for his specialized research in neurodegenerative diseases.
- Publications: Authored 7 peer-reviewed journal articles, 9 abstracts, 1 preprint, and 2 technical reports, including work in highly ranked journals in gerontology and neuroscience.
- Citations: His research has been cited 11 times, with multiple papers ranked among the most-cited in their publication years, underscoring their significance in the field.
- Peer Review Service: Completed at least 5 reviews for prestigious journals, including those focused on neuroscience and imaging, and served as a topic coordinator for an international neuroscience journal.
- Funding Support: His work has been supported by the National Center for Advancing Translational Sciences and the National Institutes of Health, reflecting the national importance of his research direction.
Expert Testimonial
The client has received 4 recommendation letters. One of the supporting letters highlighted the impact of his work:
“The high quality of his research is clearly shown by his record of peer-reviewed publications and service. [The Client]’s research in the neuroscience field is undoubtedly of benefit to both the United States and global research communities.”
NIW Approval and Outlook
The approval of this NIW petition confirms the client’s proven ability to make significant contributions to neuroscience and public health. NAILG is proud to have guided this researcher to accomplish this through a successful petition. His ongoing work in developing advanced neuroimaging biomarkers and diagnostic tools will continue to shape the early detection and treatment of neurodegenerative diseases, benefitting both US healthcare and society at large.

